Show simple item record

dc.contributor.authorde Bono, JS
dc.contributor.authorHansen, A
dc.contributor.authorChoudhury, AD
dc.contributor.authorCook, Natalie
dc.contributor.authorHeath, EI
dc.contributor.authorHigano, C
dc.contributor.authorLinch, M
dc.contributor.authorMartin-Liberal, J
dc.contributor.authorRathkopf, DE
dc.contributor.authorWisinski, KB
dc.contributor.authorBarry, S
dc.contributor.authorde Bruin, E
dc.contributor.authorBrugger, W
dc.contributor.authorColebrook, S
dc.contributor.authorKlinowska, T
dc.contributor.authorMoschetta, M
dc.contributor.authorMortimer, PGS
dc.contributor.authorSiu, LL
dc.contributor.authorShapiro, G
dc.date.accessioned2019-04-29T09:48:51Z
dc.date.available2019-04-29T09:48:51Z
dc.date.issued2018en
dc.identifier.citationde Bono JS, Hansen A, Choudhury AD, Cook N, Heath EI, Higano C, et al. 833P AZD8186, a potent and selective inhibitor of PI3K?/?, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). Annals of Oncology. 2018;29(suppl_8).en
dc.identifier.pmidNo PMIDen
dc.identifier.doi10.1093/annonc/mdy284.042en
dc.identifier.urihttp://hdl.handle.net/10541/621715
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdy284.042en
dc.titleAZD8186, a potent and selective inhibitor of PI3Kb/d, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Institute of Cancer Research and Royal Marsden, London, UKen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2020-04-20T10:47:28Z


Files in this item

Thumbnail
Name:
561567.pdf
Size:
114.6Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record